Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has gained recent popularity in its effective management of type 2 diabetes mellitus (T2DM) and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.